18251-1-AP

antibody from Proteintech Group

Targeting: PDCD1LG2 B7-DC, bA574F11.2, Btdc, CD273, PD-L2, PDL2

Provider product page for 18251-1-AP

Western blot

ELISA

Immunohistochemistry

Antibody data

Antibody Data
Antigen structure
References [15]
Comments [0]
Validations [0]

Submit

Product number: 18251-1-AP - Provider product page
Provider: Proteintech Group
Product name: PD-L2/CD273 antibody
Antibody type: Polyclonal
Description: PD-L2/CD273 antibody (Cat. #18251-1-AP) is a rabbit polyclonal antibody that shows reactivity with human, mouse, rat and has been validated for the following applications: IHC, WB,ELISA.
Reactivity: Human, Mouse, Rat
Host: Rabbit
Conjugate: Unconjugated
Isotype: IgG
Vial size: 20ul, 150ul

PDCD1LG2 protein structure - 18251-1-AP shown in red.

Submitted references Vimentin, inversely correlating with infiltration of CD8 + T lymphocytes, promotes nuclear translocation of PD-L1 in esophageal squamous cell carcinoma.

Liang Y, He S, Liu Q, Liu T, Tan Y, Peng T, Huang C, Lu X, Zheng S
Biochimica et biophysica acta. Molecular cell research 2024 Oct;1871(7):119781

LRP5 competes for SPOP binding to enhance tumorigenesis mediated by Daxx and PD-L1 in prostate cancer.

Gan S, Qu F, Zhang X, Pan X, Xu D, Cui X, Hou J
Experimental cell research 2024 Jan 1;434(1):113857

Isothiocyanates attenuate immune checkpoint blockage therapy in gastric cancer via induction of PD-L1 expression.

Zhang Q, Cao W, Yang C, Hong L, Geng S, Han H, Zhong C
The Journal of nutritional biochemistry 2023 Feb;112:109226

Intratumoral neutrophil extracellular traps are associated with unfavorable clinical outcomes and immunogenic context in pancreatic ductal adenocarcinoma.

Chen X, Ma H, Mo S, Yu S, Lu Z, Chen J
Frontiers in immunology 2022;13:1027459

Treatment with eFT-508 increases chemosensitivity in breast cancer cells by modulating the tumor microenvironment.

Yang ZY, Jiang CW, Zhang WL, Sun G
Journal of translational medicine 2022 Jun 18;20(1):276

Differential expression of PD‑L1 and PD‑L2 is associated with the tumor microenvironment of TILs and M2 TAMs and tumor differentiation in non‑small cell lung cancer.

Sumitomo R, Huang CL, Fujita M, Cho H, Date H
Oncology reports 2022 Apr;47(4)

Programmed death ligand 2 expression plays a limited role in adenocarcinomas of the gastroesophageal junction after preoperative chemotherapy.

Jomrich G, Kollmann D, Wilfing L, Radosavljevic S, Ramazanova D, Ristl R, Grose RP, Ilhan-Mutlu A, Preusser M, Fassnacht C, Tsai YC, Guenova E, Schoppmann SF
European surgery : ACA : Acta chirurgica Austriaca 2021;53(6):287-293

ANO9 regulates PD-L2 expression and binding ability to PD-1 in gastric cancer.

Katsurahara K, Shiozaki A, Kosuga T, Shimizu H, Kudou M, Arita T, Konishi H, Komatsu S, Kubota T, Fujiwara H, Okamoto K, Kishimoto M, Konishi E, Otsuji E
Cancer science 2021 Mar;112(3):1026-1037

Cisplatin remodels the tumor immune microenvironment via the transcription factor EB in ovarian cancer.

Liu W, Wang Y, Xie Y, Dai T, Fan M, Li C, Zou Y
Cell death discovery 2021 Jun 5;7(1):136

IFI30 expression is an independent unfavourable prognostic factor in glioma.

Liu X, Song C, Yang S, Ji Q, Chen F, Li W
Journal of cellular and molecular medicine 2020 Nov;24(21):12433-12443

Programmed death-ligand 2 (PD-L2) expression in bladder cancer.

Yang Y, Wang X, Bai Y, Feng D, Li A, Tang Y, Wei X, Han P
Urologic oncology 2020 Jun;38(6):603.e9-603.e15

PD-L2 expression is correlated with the molecular and clinical features of glioma, and acts as an unfavorable prognostic factor.

Wang ZL, Li GZ, Wang QW, Bao ZS, Wang Z, Zhang CB, Jiang T
Oncoimmunology 2019;8(2):e1541535

Aberrant PD-1 ligand expression contributes to the myocardial inflammatory injury caused by Coxsackievirus B infection.

Wang T, Chen S, Wang X, Huang Y, Qiu J, Fei Y, Chaulagain A, Chen Y, Wang Y, Lin L, Yan B, Wang Y, Wang W, Zhao W, Zhong Z
Antiviral research 2019 Jun;166:1-10

PD-L1, LAG3, and HLA-DR are increasingly expressed during smoldering myeloma progression.

Mussetti A, Pellegrinelli A, Cieri N, Garzone G, Dominoni F, Cabras A, Montefusco V
Annals of hematology 2019 Jul;98(7):1713-1720

Targeting amphiregulin (AREG) derived from senescent stromal cells diminishes cancer resistance and averts programmed cell death 1 ligand (PD-L1)-mediated immunosuppression.

Xu Q, Long Q, Zhu D, Fu D, Zhang B, Han L, Qian M, Guo J, Xu J, Cao L, Chin YE, Coppé JP, Lam EW, Campisi J, Sun Y
Aging cell 2019 Dec;18(6):e13027

No comments: Submit comment

No validations: Submit validation data